Comparative Pharmacology
Head-to-head clinical analysis: CATAPRES versus CATAPRES TTS 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAPRES versus CATAPRES TTS 2.
CATAPRES vs CATAPRES-TTS-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance and lowered blood pressure.
Clonidine is a centrally acting alpha-2 adrenergic agonist that stimulates alpha-2 adrenergic receptors in the brainstem, activating inhibitory neurons and reducing sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance, heart rate, and blood pressure.
Oral: 0.1 mg twice daily initially, titrate to 0.2-0.6 mg/day in divided doses; maximum 2.4 mg/day. Transdermal: 0.1 mg/24 hours patch applied every 7 days, titrate to 0.2-0.3 mg/24 hours.
Transdermal patch delivering 0.2 mg/day clonidine applied every 7 days to hairless area of upper arm or chest.
None Documented
None Documented
Terminal elimination half-life: 12-16 hours in normal renal function; prolonged to 48-96 hours in severe renal impairment. Use with caution in CKD.
Terminal elimination half-life: 12–16 hours (up to 48 hours following transdermal administration due to continued absorption from the skin depot).
Renal: ~65% (40-50% unchanged; 20-25% as metabolites). Biliary/fecal: ~35% (conjugated metabolites).
Renal: ~65% as unchanged drug; biliary/fecal: ~20% as metabolites; about 15% eliminated as metabolites in urine.
Category C
Category C
Central Alpha-Agonist
Central Alpha-Agonist